Habeebunnisa Begum

Habeebunnisa Begum

Auto-generated profile, based on publicly available information

Habeebunnisa Begum

Rutgers University New Jersey Medical School 1 Department of Microbiology, Biochemistry and Molecular Genetics Newark, NJ

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in BioTechniques
Verified
Journal Article
Open access
HBHabeebunnisa Begum
Habeebunnisa Begum
PMPeriyasamy Murugesan
Periyasamy Murugesan
ATAnjana Devi Tangutur
Anjana Devi Tangutur
Western blotting (WB), also known as immunoblotting, is a well-known molecular biology method that biologists often use to investigate many features of the protein, ranging from basic protein analy... Method summary Western blotting is a powerful technique widely used in scientific and medical research to separate and detect various key proteins, especially the less abundant ones in critical dia...

21 October 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
DDDaiyong Deng
Daiyong Deng
HBHabeebunnisa Begum
Habeebunnisa Begum
TLTong Liu
Tong Liu
JZJiangyan Zhang
Jiangyan Zhang
QZQiang Zhang
Qiang Zhang
PHPingping Hou
Pingping Hou
Resistance to KRAS therapy in pancreatic ductal adenocarcinoma (PDAC) involves cellular plasticity, particularly the epithelial-to-mesenchymal transition (EMT), which poses challenges for effective targeting. Chronic pancreatitis, a known risk factor for PDAC, elevates TGFβ levels in the tumor microenvironment (TME), promoting resistance to KRAS therapy. Mechanistically, TGFβ induces the formation of a novel protein complex composed of SMAD3, SMAD4, and the nuclear factor NFAT5, triggering EMT and resistance by activating key mediators such as S100A4. Inhibiting NFAT5 attenuates pancreatitis-induced resistance to KRAS inhibition and extends mouse survival. Additionally, TGFβ stimulates PDAC cells to secrete CCL2, recruiting macrophages that contribute to KRAS bypass through paracrine S100A4. Our findings elucidate the role of TGFβ signaling in EMT-associated KRAS therapy resistance and identify NFAT5 as a druggable target. Targeting NFAT5 could disrupt this regulatory network, offering a potential avenue for preventing resistance in PDAC.


19 May 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
NCNagaraju Chirra
Nagaraju Chirra
HBHabeebunnisa Begum
Habeebunnisa Begum
NANaga Pranathi Abburi
Naga Pranathi Abburi
RBRakesh Kumar Bollikanda
Rakesh Kumar Bollikanda
PMPeriyasamy Murugesan
Periyasamy Murugesan
ATAnjana Devi Tangutur
Anjana Devi Tangutur